<DOC>
	<DOCNO>NCT00876772</DOCNO>
	<brief_summary>Amyotrophic Lateral Sclerosis ( ALS ) adult neurodegenerative disease cause selective degeneration motor nerve cell cortex myelon . As result motor neurodegeneration , progredient paralysis extremity speak , swallow , breathe musculature develop . ALS lead death respiratory insufficiency mean course 3-5 year . More 80 % ALS patient present clinically significant undesirable weight loss . The cause weight loss heterogeneous . Fundamentally , investigator must distinguish malnutrition , cachexia loss appetite . Loss weight independent prognosis factor ALS . Effective treatment undesirable weight loss important therapy goal ALS . The researcher propose investigational therapy ALS oral administration Olanzapine . The rationale study base weight-increasing effect OLN . The clinical trial aim employ OLN-induced weight gain weight stabilization symptomatic therapy loss appetite . An undesired weight loss least 10 % body weight reduced weight-increasing effect OLN . The hypothesis state undesired weight loss ALS patient treatment OLN 10mg combination Riluzole ( RIL ) 100mg least 20 percentage point less treatment placebo combination 100 mg RIL .</brief_summary>
	<brief_title>Olanzapine Treatment Appetite Loss Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>After randomization , placebo-controlled parallel group treatment 10 mg OLN combination standard treatment Riluzole ( 100mg/day ) ( Group 1 ) comparison treatment placebo combination 100 mg RIL ( Group 2 ) . Study drug provide 5 mg tablet . OLN begin initial dosage 5 mg/day one week . The intake occur evening hour form capsule contain 5 mg OLN . The evening dose Riluzole take together OLN medication . After one week ( day 8 ) , dose increase 10 mg OLN/day , take form two capsule timepoint evening hour . This dose continue 51 week .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients age 18 80 year old Clinical diagnosis definitive , probable , possible ALS ( revise El Escorial Criteria ) diagnosis clinical ALSvariants Progressive Muscle Atrophy ( PMA ) Sporadic familial ALS Beginning symptom paralysis least 6 month prior Treatment steady dose RIL 100 mg/day least 1 month A score ≤ 28 symptomoriented Council Nutrition appetite questionnaire ( CNAQ ) appetite evaluate Patient consent Patients know hypersensitivity OLN , RIL , one active ingredient Percutaneous Endoscopic Gastronomy ( PEG ) Clinically significant eat disorder Deliberate weight loss Underlying consumptive disease undesired weight loss Overweight BMI ≥ 25 kg/m2 Clinically significant hypotonia history recurrent syncope ( &gt; 1 syncope ) Clinically severe concomitant illness , include psychiatric illness Pregnant nursing woman Severe neutropenia ( &lt; 750/mm3 ) Open angle glaucoma Diabetes mellitus Prostatic hyperplasia Extrapyramidal movement disorder include late dyskinesia Dementia incompetence grant inform consent Clinically significant EKG change EKG proof QT time correct accord Fridericia ( QTcF ) &gt; 500 m Treatment substance metabolize CytochromP450System CYP1A2 ( e. g. Carbamazepine , Fluvoxamin , Ciprofloxacin ) Treatment Mirtazapine within past 3 month Treatment steroid appetitestimulating substance include anabolics within past 3 month Treatment Valproat within past 3 month Treatment hepatotoxic medicine Treatment tetrahydrocannabinol within past 3 month Treatment another atypical typical neuroleptic within past 3 month Treatment study medication &lt; 1 month begin study Destructive use psychotropic substance within past 3 month Destructive use alcohol Laboratory parameter outside normal range associate clinically significant cardiovascular , pulmonologic , hematologic , hepatological , metabolic , renal disease interfere interpretation clinical study require medication permit study protocol Elevation serum transaminase level ( ALT/AST ) 3times upper normal value Elevation bilirubin gamma glutamyl transferase level ( GGT ) beyond maximum normal value History cardiopulmonary reanimation und prevention sudden cardiac death History clinically significant EKG change History thrombotic event include deep leg vein thrombosis pulmonary artery embolism History paralytic ileus History epilepsy episodic seizure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>ALS</keyword>
	<keyword>olanazapine</keyword>
	<keyword>Loss Apptetite</keyword>
	<keyword>Appetite Loss</keyword>
	<keyword>Malnutrition</keyword>
	<keyword>Cachexia</keyword>
	<keyword>Zyprexa</keyword>
</DOC>